
SI-BONE, Inc.: stock overview
Price
$23.44
November 13, 2026Market cap $1.0B
What Ploutos Investor adds for SI-BONE
Part of Ploutos Investor, €9.99 a month
- The full history: 9 fiscal years, from 2017
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
SI-BONE had revenue of $221M over the last 12 months and a net loss of $14M. Revenue grew by 22.3% a year on average over the last 5 years. It holds more cash than debt, by $104M. It pays no dividend.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.
Its SEC filings- Market cap
- $1.0B
- 44.17M shares
- P/E
- –
- Revenue, 12 months
- $221M
- +22.3% a year over 5 years
- Net margin
- -6.2%
- 2025: -9.4%, above 35% of its industry
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
+20.3% a year over 2 years
Fiscal years in figures
SIBN's revenue, profit, cash flow and dividend with each year-end price, from 2017 to 2022, 6 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $862M
- $1.0B
- Enterprise value
- $931M
- P/E
- –
- EV / EBIT
- –
- EV / Revenue
- 4.2
- P/B 3-year median: 4.9
- 5.6
- FCF yield 3-year median: -3.1%
- –
- Earnings yield 3-year median: -5.3%
- –
Profitability
- Gross margin
- 79.4%
- Operating margin
- -7.6%
- Net margin 3-year median: -18.5%
- -6.2%
- ROIC
- -6.2%
- ROIC, 5-year average
- -19.9%
- ROE
- -7.6%
Growth
- Revenue, yearly change
- +20.2%
- EPS, yearly change
- –
- FCF, yearly change
- –
- Revenue, average a year
- +22.3%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $139M
- Total debt
- $43M
- Of which operating leases
- $7.1M
- Net cash
- $104M
- Net debt / EBITDA
- –
- Interest cover
- -6.9x
- Current ratio
- 7.58
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +4.0%
Against its industry
Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 38).
Gross margin
79.6%
Above 93% of the 161 companies in its industry, and 95% of all.
Operating margin
-11.1%
Above 31% of the 186 companies in its industry, and 19% of all.
Net margin
-9.4%
Above 35% of the 189 companies in its industry, and 19% of all.
ROE
-10.7%
Above 34% of the 174 companies in its industry, and 19% of all.
ROA
-7.9%
Above 33% of the 190 companies in its industry, and 16% of all.
Revenue growth
20.2%
Above 83% of the 186 companies in its industry, and 81% of all.
From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- SI-BONE, Inc.
- CIK
- 1459839
- Exchange
- NASDAQ
- Industry (SIC)
- 3841 · Surgical & Medical Instruments & Apparatus
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 44.17M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with SIBN
- JNJJohnson & Johnson+0,00%Compare with SIBN
- ABBVAbbVie+0,00%Compare with SIBN
- UNHUnitedHealth+0,00%Compare with SIBN
- MRKMerck & Company+0,00%Compare with SIBN
- AMGNAmgen+0,00%Compare with SIBN
- TMOThermo Fisher Scientific+0,00%Compare with SIBN
- ABTAbbott Laboratories+0,00%Compare with SIBN
The full analysis
What do SI-BONE's filings show?
These are SI-BONE's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is SIBN's market cap?
SI-BONE, Inc.'s market cap is $1.0B, at a price of $23.44 on November 13, 2026 and 44.17M shares.
How much revenue does SIBN have?
SI-BONE had revenue of $221M over the last 12 months. Over the last 5 years it changed by +22.3% a year on average.
Does SIBN pay a dividend?
No. SI-BONE paid no regular dividend over the last 12 months.
Where do the figures come from?
From SI-BONE, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.